Sleep Apnea Device Maker ResMed Is A Durable MedTech, With Positive Fundamentals, Says Analyst
ResMed(RMD) Benzinga·2024-10-25 23:15
On Thursday, ResMed Inc RMD reported first-quarter adjusted EPS of $2.20, up 34% year over year, beating the consensus of $2.04. The company reported sales of $1.224 billion, up 11%, beating the consensus of $1.18 billion, driven by increased demand for sleep devices and masks portfolio and strong growth across the Residential Care Software business. Residential Care Software revenue increased by 12% on a constant currency basis, reflecting continued organic growth in the Residential Care Software portfolio ...